SPYRE THERAPEUTICS, INC. Operating Expenses
SPYRE THERAPEUTICS, INC. (SYRE) reported Operating Expenses of $41.64 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-04
- SPYRE THERAPEUTICS, INC. operating expenses for the quarter ending 2026-06-30 was $41.64M, a 0.71% decline year-over-year.
- SPYRE THERAPEUTICS, INC. operating expenses for the quarter ending 2026-03-31 was $45.64M, a 14.80% decline year-over-year.
- SPYRE THERAPEUTICS, INC. operating expenses for the quarter ending 2025-12-31 was $57.17M, a 6.66% decline year-over-year.
- SPYRE THERAPEUTICS, INC. operating expenses for the quarter ending 2025-09-30 was $56.89M, a 2.70% increase year-over-year.
- SPYRE THERAPEUTICS, INC. operating expenses for fiscal 2025 was $209.56M, a 0.48% increase from fiscal 2024.
- SPYRE THERAPEUTICS, INC. operating expenses for fiscal 2024 was $208.57M, a 14.24% decline from fiscal 2023.
- SPYRE THERAPEUTICS, INC. operating expenses for fiscal 2023 was $243.19M, a 179.17% increase from fiscal 2022.
- SPYRE THERAPEUTICS, INC. operating expenses for fiscal 2022 was $87.11M, a 3.23% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $41.64M 10-Q · filed 2026-08-04 | $87.28M 10-Q · filed 2026-08-04 | $144.45M derived: sum of 3 quarters · filed 2026-08-04 | $201.34M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $45.64M 10-Q · filed 2026-05-05 | $102.81M derived: sum of 2 quarters · filed 2026-05-05 | $159.70M derived: sum of 3 quarters · filed 2026-05-05 | $201.64M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $57.17M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $114.06M derived: sum of 2 quarters · filed 2026-02-19 | $156.00M derived: sum of 3 quarters · filed 2026-08-04 | $209.56M 10-K · filed 2026-02-19 |
| 2025-09-30 | $56.89M 10-Q · filed 2025-11-04 | $98.82M derived: sum of 2 quarters · filed 2026-08-04 | $152.39M 10-Q · filed 2025-11-04 | $213.64M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $41.94M 10-Q · filed 2026-08-04 | $95.50M 10-Q · filed 2026-08-04 | $156.75M derived: sum of 3 quarters · filed 2026-08-04 | $212.15M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $53.57M 10-Q · filed 2026-05-05 | $114.82M derived: sum of 2 quarters · filed 2026-05-05 | $170.21M derived: sum of 3 quarters · filed 2026-05-05 | $214.36M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $61.25M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $116.64M derived: sum of 2 quarters · filed 2026-02-19 | $160.79M derived: sum of 3 quarters · filed 2026-02-19 | $208.57M 10-K · filed 2026-02-19 |
| 2024-09-30 | $55.39M 10-Q · filed 2025-11-04 | $99.54M derived: sum of 2 quarters · filed 2025-11-04 | $147.31M 10-Q · filed 2025-11-04 | $193.23M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-06-30 | $44.15M 10-Q · filed 2025-08-05 | $91.92M 10-Q · filed 2025-08-05 | $137.84M derived: sum of 3 quarters · filed 2026-02-19 | $156.17M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-03-31 | $47.77M 10-Q · filed 2025-05-08 | $93.69M derived: sum of 2 quarters · filed 2026-02-19 | $112.03M derived: sum of 3 quarters · filed 2026-02-19 | $271.96M derived: sum of 4 quarters · filed 2026-02-19 |
| 2023-12-31 | $45.91M derived: 10-K 12 month − 10-Q/A 9 month · filed 2026-02-19 | $64.25M derived: sum of 2 quarters · filed 2026-02-19 | $224.19M derived: sum of 3 quarters · filed 2026-02-19 | $243.19M 10-K · filed 2026-02-19 |
| 2023-09-30 | $18.34M 10-Q/A · filed 2024-11-18 | $178.27M derived: sum of 2 quarters · filed 2024-11-18 | $197.28M 10-Q/A · filed 2024-11-18 | $216.60M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $159.93M 10-Q/A · filed 2024-11-18 | $178.94M 10-Q/A · filed 2024-11-18 | $198.27M derived: sum of 3 quarters · filed 2025-02-27 | $217.20M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $19.00M 10-Q/A · filed 2024-11-18 | $38.33M derived: sum of 2 quarters · filed 2025-02-27 | $57.26M derived: sum of 3 quarters · filed 2025-02-27 | $80.31M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $19.33M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $38.26M derived: sum of 2 quarters · filed 2025-02-27 | $61.31M derived: sum of 3 quarters · filed 2025-02-27 | $87.11M 10-K · filed 2025-02-27 |
| 2022-09-30 | $18.93M 10-Q · filed 2023-11-09 | $41.98M derived: sum of 2 quarters · filed 2023-11-09 | $67.78M 10-Q · filed 2023-11-09 | $91.87M derived: sum of 4 quarters · filed 2024-11-18 |
| 2022-06-30 | $23.05M 10-Q · filed 2023-08-11 | $48.85M 10-Q · filed 2023-08-11 | $72.94M derived: sum of 3 quarters · filed 2024-11-18 | $94.63M derived: sum of 4 quarters · filed 2024-11-18 |
| 2022-03-31 | $25.80M 10-Q · filed 2023-05-11 | $49.89M derived: sum of 2 quarters · filed 2024-11-18 | $71.58M derived: sum of 3 quarters · filed 2024-11-18 | $91.98M derived: sum of 4 quarters · filed 2024-11-18 |
| 2021-12-31 | $24.09M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-11-18 | $45.78M derived: sum of 2 quarters · filed 2024-11-18 | $66.18M derived: sum of 3 quarters · filed 2024-11-18 | $84.39M 10-K/A · filed 2024-11-18 |
| 2021-09-30 | $21.69M 10-Q · filed 2022-11-03 | $42.09M derived: sum of 2 quarters · filed 2022-11-03 | $60.30M 10-Q · filed 2022-11-03 | $83.08M derived: sum of 4 quarters · filed 2023-03-02 |
| 2021-06-30 | $20.40M 10-Q · filed 2022-08-04 | $38.61M 10-Q · filed 2022-08-04 | $61.39M derived: sum of 3 quarters · filed 2023-03-02 | $79.51M derived: sum of 4 quarters · filed 2023-03-02 |
| 2021-03-31 | $18.21M 10-Q · filed 2022-05-05 | $40.98M derived: sum of 2 quarters · filed 2023-03-02 | $59.11M derived: sum of 3 quarters · filed 2023-03-02 | $80.67M derived: sum of 4 quarters · filed 2023-03-02 |
| 2020-12-31 | $22.78M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | $40.90M derived: sum of 2 quarters · filed 2023-03-02 | $62.46M derived: sum of 3 quarters · filed 2023-03-02 | $81.48M 10-K · filed 2023-03-02 |
| 2020-09-30 | $18.12M 10-Q · filed 2021-11-04 | $39.68M derived: sum of 2 quarters · filed 2021-11-04 | $58.70M 10-Q · filed 2021-11-04 | $80.61M derived: sum of 4 quarters · filed 2022-03-08 |
| 2020-06-30 | $21.56M 10-Q · filed 2021-08-05 | $40.58M 10-Q · filed 2021-08-05 | $62.49M derived: sum of 3 quarters · filed 2022-03-08 | $84.64M derived: sum of 4 quarters · filed 2022-03-08 |
| 2020-03-31 | $19.02M 10-Q · filed 2021-05-10 | $40.93M derived: sum of 2 quarters · filed 2022-03-08 | $63.08M derived: sum of 3 quarters · filed 2022-03-08 | $81.70M derived: sum of 4 quarters · filed 2022-03-08 |
| 2019-12-31 | $21.91M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-08 | $44.05M derived: sum of 2 quarters · filed 2022-03-08 | $62.68M derived: sum of 3 quarters · filed 2022-03-08 | $80.33M 10-K · filed 2022-03-08 |
| 2019-09-30 | $22.15M 10-Q · filed 2020-11-05 | $40.77M derived: sum of 2 quarters · filed 2020-11-05 | $58.42M 10-Q · filed 2020-11-05 | $73.73M derived: sum of 4 quarters · filed 2021-03-18 |
| 2019-06-30 | $18.62M 10-Q · filed 2020-08-10 | $36.28M 10-Q · filed 2020-08-10 | $51.58M derived: sum of 3 quarters · filed 2021-03-18 | $63.83M derived: sum of 4 quarters · filed 2021-03-18 |
| 2019-03-31 | $17.66M 10-Q · filed 2020-05-07 | $32.96M derived: sum of 2 quarters · filed 2021-03-18 | $45.20M derived: sum of 3 quarters · filed 2021-03-18 | $57.25M derived: sum of 4 quarters · filed 2021-03-18 |
| 2018-12-31 | $15.30M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-18 | $27.55M derived: sum of 2 quarters · filed 2021-03-18 | $39.60M derived: sum of 3 quarters · filed 2021-03-18 | $49.35M 10-K · filed 2021-03-18 |
| 2018-09-30 | $12.24M 10-Q · filed 2019-11-06 | $24.29M derived: sum of 2 quarters · filed 2019-11-06 | $34.05M 10-Q · filed 2019-11-06 | $42.15M derived: sum of 4 quarters · filed 2020-02-24 |
| 2018-06-30 | $12.05M 10-Q · filed 2019-08-06 | $21.80M 10-Q · filed 2019-08-06 | $29.91M derived: sum of 3 quarters · filed 2020-02-24 | $39.17M derived: sum of 4 quarters · filed 2020-02-24 |
| 2018-03-31 | $9.76M 10-Q · filed 2019-05-07 | $17.86M derived: sum of 2 quarters · filed 2020-02-24 | $27.12M derived: sum of 3 quarters · filed 2020-02-24 | $35.32M derived: sum of 4 quarters · filed 2020-02-24 |
| 2017-12-31 | $8.11M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-24 | $17.37M derived: sum of 2 quarters · filed 2020-02-24 | $25.57M derived: sum of 3 quarters · filed 2020-02-24 | $32.88M 10-K · filed 2020-02-24 |
| 2017-09-30 | $9.26M 10-Q · filed 2018-11-08 | $17.46M derived: sum of 2 quarters · filed 2018-11-08 | $24.77M 10-Q · filed 2018-11-08 | $31.56M derived: sum of 4 quarters · filed 2019-03-07 |
| 2017-06-30 | $8.20M 10-Q · filed 2018-08-09 | $15.51M 10-Q · filed 2018-08-09 | $22.30M derived: sum of 3 quarters · filed 2019-03-07 | $29.75M derived: sum of 4 quarters · filed 2019-03-07 |
| 2017-03-31 | $7.31M 10-Q · filed 2018-05-08 | $14.10M derived: sum of 2 quarters · filed 2019-03-07 | $21.55M derived: sum of 3 quarters · filed 2019-03-07 | $28.42M derived: sum of 4 quarters · filed 2019-03-07 |
| 2016-12-31 | $6.79M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07 | $14.24M derived: sum of 2 quarters · filed 2019-03-07 | $21.11M derived: sum of 3 quarters · filed 2019-03-07 | $26.53M 10-K · filed 2019-03-07 |
| 2016-09-30 | $7.45M 10-Q · filed 2017-11-07 | $14.32M derived: sum of 2 quarters · filed 2017-11-07 | $19.74M 10-Q · filed 2017-11-07 | $25.33M derived: sum of 4 quarters · filed 2018-03-13 |
| 2016-06-30 | $6.87M 10-Q · filed 2017-08-09 | $12.29M 10-Q · filed 2017-08-09 | $17.88M derived: sum of 3 quarters · filed 2018-03-13 | $22.37M derived: sum of 4 quarters · filed 2018-03-13 |
| 2016-03-31 | $5.43M 10-Q · filed 2017-05-09 | $11.01M derived: sum of 2 quarters · filed 2018-03-13 | $15.50M derived: sum of 3 quarters · filed 2018-03-13 | $20.36M derived: sum of 4 quarters · filed 2018-03-13 |
| 2015-12-31 | $5.58M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-13 | $10.07M derived: sum of 2 quarters · filed 2018-03-13 | $14.93M derived: sum of 3 quarters · filed 2018-03-13 | $17.40M 10-K · filed 2018-03-13 |
| 2015-09-30 | $4.49M 10-Q · filed 2016-11-09 | $9.35M derived: sum of 2 quarters · filed 2016-11-09 | $11.82M 10-Q · filed 2016-11-09 | |
| 2015-06-30 | $4.86M 10-Q · filed 2016-08-09 | $7.33M 10-Q · filed 2016-08-09 | ||
| 2015-03-31 | $2.47M 10-Q · filed 2016-05-19 | |||
| 2014-12-31 | $8.90M 10-K · filed 2017-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |